Associated tags: Health, OTCQB, SAN, POC, CE, MHRA, Health care, C-reactive protein, Medication, Analyser, PCT, Sepsis, Medical device, CRP, Point-of-care testing, LAC, Procalcitonin, Security (finance), Pharmaceutical industry, Elab
Locations: SAN LEANDRO, CA, US, EUROPE, WOODLEY, UNITED STATES
CE,
Specialization,
Health care,
OTCQB,
C-reactive protein,
Medication,
Analyser,
PCT,
Sepsis,
Animal,
CRP,
Investment,
SAN,
Point-of-care testing,
POC,
LAC,
Procalcitonin,
MHRA,
Medical device To date, Woodley has made a total of $570,000 of equity investments in the Company.
Key Points:
- To date, Woodley has made a total of $570,000 of equity investments in the Company.
- As announced on November 9, 2022 , Nanomix and Woodley entered into an exclusive distribution agreement.
- Thomas Schlumpberger, Chief Executive Officer of Nanomix, stated, “I am very pleased to receive Woodley’s additional equity investment which shows continued confidence in Nanomix and our technology.
- Woodley brings significant product development and commercial expertise that allows us to expand our efforts into the veterinary market earlier than planned.
Retrieved on:
Wednesday, January 25, 2023
Madrona Venture Group,
Wells Fargo,
LBO,
Honors colleges and programs,
GE Capital,
EBay,
CFO,
OTCQB,
Software as a service,
SAN,
IPO,
Utah State University Honors Program,
Name,
BA,
Netflix,
Brown University,
POC,
Management,
Symantec SAN LEANDRO, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Nanomix Corporation (OTCQB: NNMX) (“Nanomix” or the “Company”), a leader in mobile, affordable, point-of-care (POC) diagnostics, today announced the appointment of Christopher R. Hetterly as Chief Financial Officer (CFO).
Key Points:
- SAN LEANDRO, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Nanomix Corporation (OTCQB: NNMX) (“Nanomix” or the “Company”), a leader in mobile, affordable, point-of-care (POC) diagnostics, today announced the appointment of Christopher R. Hetterly as Chief Financial Officer (CFO).
- Mr. Hetterly is a financial executive and entrepreneur, with over 25 years of financial leadership and banking experience.
- Thomas Schlumpberger, Nanomix CEO, stated, “We are excited to welcome Chris to the Nanomix management team as our CFO.
- Chris has more than 25 years in senior financial roles encompassing debt and equity financing, corporate development, and business development.
Retrieved on:
Tuesday, November 29, 2022
Growth,
SAN,
GEPA,
CRP,
Business manager,
Procalcitonin,
Health care,
PCT,
C-reactive protein,
Health,
Caregiver,
POC,
ISO 9001:2015,
Security (finance),
Analyser,
MHRA,
CE,
Point of care,
Research,
Elab,
OTCQB,
LAC,
Point-of-care testing,
Medication,
Sepsis,
Medical device,
Pharmaceutical industry John Hardesky, Chief Commercial Officer of Nanomix, stated, Gepa has significant experience in this increasingly complex and important segment of critical infections, sepsis, and antibiotic stewardship.
Key Points:
- John Hardesky, Chief Commercial Officer of Nanomix, stated, Gepa has significant experience in this increasingly complex and important segment of critical infections, sepsis, and antibiotic stewardship.
- We are excited to support and align with Gepa on an ambitious execution plan to bring our technology to a competitive market like Italy.
- Riccardo Figus, Business Manager of Gepa, commented, The GEPA team is very excited to develop the Italian market for the new eLab, a true Point of Care device.
- The agreement with Nanomix enables us to offer our customers an innovative solution for the fight against sepsis.
Retrieved on:
Wednesday, November 9, 2022
SAN,
GLOBE,
C-reactive protein,
CRP,
Elab,
Dog,
Procalcitonin,
Forward-looking statement,
MHRA,
PCT,
Health care,
U.S. Securities and Exchange Commission,
Cat,
Health,
LAC,
Technology,
CE,
Diagnosis,
Specialization,
Disease,
Sepsis,
Mortality,
Decision-making,
Analyser,
Point-of-care testing,
Time,
Medication,
Company,
OTCQB,
Human,
Skin,
Contract research organization,
Growth,
Security (finance),
Animal,
Infection,
Industry,
History,
POC,
Pharmaceutical industry,
Medical device Mike Wickham, Managing Director of Woodley, commented,Woodley supplies equipment for all aspects of laboratory diagnostics in the veterinary market with a specialization in emergency and critical care devices.
Key Points:
- Mike Wickham, Managing Director of Woodley, commented,Woodley supplies equipment for all aspects of laboratory diagnostics in the veterinary market with a specialization in emergency and critical care devices.
- Currently, sepsis in animals has no reliable markers which have a predictive indicator and certainly not at the POC.
- We are excited that a POC device can be developed to treat animals and Woodley is proud to be involved with Nanomix.
- The Nanmix eLab system is a mobile, hand-held immunoassay and chemistry diagnostic system designed for the needs of rapid point-of-care testing.
Public health,
Company,
Health care,
Growth,
Medication,
Time,
CE,
SAN,
C-reactive protein,
Industry,
Solution,
GLOBE,
Elab,
POC,
PCT,
Sepsis,
LAC,
Point-of-care testing,
Health,
OTCQB,
Infection,
MHRA,
Microbiology,
U.S. Securities and Exchange Commission,
Forward-looking statement,
Molecular biology,
Procalcitonin,
Decision-making,
Analyser,
CRP,
Technology,
Pneumonia,
Pleasure,
Marketing,
Security (finance),
Diagnosis,
United Kingdom,
Medical device,
Pharmaceutical industry Mast will market and distribute the Nanmix eLabsystem in the United Kingdom, Germany, France, Ireland and South Africa.
Key Points:
- Mast will market and distribute the Nanmix eLabsystem in the United Kingdom, Germany, France, Ireland and South Africa.
- John Hardesky, Chief Commercial Officer of Nanomix, stated, It has been a pleasure working with The Mast Group to bring this agreement to fruition.
- The Nanmix eLab system is a mobile, hand-held immunoassay and chemistry diagnostic system designed for the needs of rapid point-of-care testing.
- Mast Group Ltd.offers its specialized product range through its own companies plus a global network of distributors.
Retrieved on:
Thursday, October 20, 2022
SAN,
LAC,
Sepsis,
Time,
U.S. Securities and Exchange Commission,
Health care,
Growth,
MHRA,
PCT,
Diagnosis,
C-reactive protein,
Republic,
Spondyloarthropathy,
Patient,
Procalcitonin,
Medication,
Security (finance),
Point-of-care testing,
Company,
Industry,
OTCQB,
Health,
Elab,
CRP,
Analyser,
CE,
Decision-making,
GLOBE,
Forward-looking statement,
Triage,
POC,
Medical device,
Medical imaging,
Pharmaceutical industry We continue to expand our footprint internationally and gain strategic regions due to the unique benefits of the eLab system, stated Thomas Schlumpberger, Chief Executive Officer of Nanomix.
Key Points:
- We continue to expand our footprint internationally and gain strategic regions due to the unique benefits of the eLab system, stated Thomas Schlumpberger, Chief Executive Officer of Nanomix.
- In approximately 12 minutes, the eLab system can provide healthcare professionals accurate and quantitative results without sending samples to a central lab.
- Additionally, first responders and other healthcare providers can use the eLab for quick, on-the-spot assessment and triage of patients no matter where they are.
- The Nanmix eLab system is a mobile, hand-held immunoassay and chemistry diagnostic system designed for the needs of rapid point-of-care testing.
Technology,
Mobile,
Wireless,
Medical devices,
Infectious diseases,
Hospitals,
Software,
Biotechnology,
Health,
Pharmaceutical,
Corporate finance,
Stock market,
Financial economics,
Finance,
Corporations,
Reverse takeover,
Warrant,
Reverse stock split,
Mergers and acquisitions,
Stock split Investors were also issued warrants to purchase an aggregate of approximately 708.8 million shares of common stock (collectively, the Warrants).
Key Points:
- Investors were also issued warrants to purchase an aggregate of approximately 708.8 million shares of common stock (collectively, the Warrants).
- As part of the reverse merger with Nanomix, the Company will implement a reverse stock split of 173:1.
- On June 4, 2021, Nanomix, Inc. completed a reverse merger transaction with the Company.
- Following the reverse merger, the Company intends to changed its name to Nanomix Holdings, Inc., and will continue the innovative business of Nanomix.
Retrieved on:
Tuesday, February 9, 2021
Biotechnology,
FDA,
Medical devices,
Infectious diseases,
Health,
Medicine,
Medical specialties,
Branches of biology,
Medical tests,
Medical terminology,
Rapid antigen test,
Biomedical Advanced Research and Development Authority,
Emergency Use Authorization,
Antibody,
Antigen,
Coronavirus disease,
COVID-19 testing Nanomix, a leader in the development of mobile, affordable, point-of-care diagnostics, today announced that the company has submitted an Emergency Use Authorization request to the U.S. Food and Drug Administration (FDA) for the eLab COVID-19 rapid antigen test.
Key Points:
- Nanomix, a leader in the development of mobile, affordable, point-of-care diagnostics, today announced that the company has submitted an Emergency Use Authorization request to the U.S. Food and Drug Administration (FDA) for the eLab COVID-19 rapid antigen test.
- The Nanomix eLab platform and COVID-19 rapid antigen test will enable medical professionals, emergency workers, and employers to test individuals for antigens that indicate COVID-19 infection.
- By completing this EUA filing, we are one step closer to making our antigen test available to help address this remaining gap.
- Nanomix developed both the COVID-19 antigen and antibody assays in part with funding from BARDA.
Research,
Pharmaceutical,
Technology,
Medical devices,
Infectious diseases,
Hospitals,
Genetics,
Clinical trials,
Science,
Nanotechnology,
Biotechnology,
FDA,
Health,
Medicine,
Clinical medicine,
Non-profit organizations based in California,
Transhumanism,
X Prize Foundation,
Medical specialties,
Immunologic tests,
COVID-19 testing,
Coronavirus disease,
ELISA,
Nanomix,
XPRIZE Rapid COVID Testing Nanomix, a leader in the development of mobile, affordable, point-of-care diagnostics, today announced that XPRIZE has selected the companys eLab COVID-19 assay as a finalist in the XPRIZE Rapid COVID Testing competition.
Key Points:
- Nanomix, a leader in the development of mobile, affordable, point-of-care diagnostics, today announced that XPRIZE has selected the companys eLab COVID-19 assay as a finalist in the XPRIZE Rapid COVID Testing competition.
- XPRIZE Rapid COVID Testing competition is inspiring the best entrepreneurs and scientists to form teams and come together to work towards rapid, affordable COVID-19 testing at scale, and ultimately, getting the world up and running again.
- We are excited to be selected as a finalist in the XPRIZE Rapid COVID Testing, said David Ludvigson, CEO of Nanomix.
- The eLab Rapid COVID Antigen test, together with our eLab Rapid COVID Antibody test, form a complete offering for COVID-19 testing.
Retrieved on:
Wednesday, December 16, 2020
FREMONT, Calif., Dec. 16, 2020 /PRNewswire/ -- Today, Evolve Manufacturing Technologies - a leading Bay-Area contract manufacturer - announces a partnership with biotech company Nanmix to produce rapid antibody and antigen test kits in the fight against COVID-19.
Key Points:
- FREMONT, Calif., Dec. 16, 2020 /PRNewswire/ -- Today, Evolve Manufacturing Technologies - a leading Bay-Area contract manufacturer - announces a partnership with biotech company Nanmix to produce rapid antibody and antigen test kits in the fight against COVID-19.
- Nanmix CEO and medical industry veteranDavid Ludvigsonsays rather than sending manufacturing of the devices overseas, Evolve will produce these rapid point-of-care tests at its Fremont, California, facility.
- Evolve Manufacturing Technologies Inc. is a contract manufacturer that offers innovative end-to-end manufacturing services for medical device and life-sciences companies.
- Located in the heart of Silicon Valley, Evolve operates a state-of-the-art 75,000-square-foot manufacturing facility.
